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Success stories in looking for effective strategies 
against cancer often have their roots in pathology. In case 
of primary mediastinal B-cell lymphoma (PMBL), this 
was likely the recognition as a distinct subtype of diffuse 
large B-cell lymphoma (DLBCL) in the early 80s [1, 2]. 
Initially a controversial entity, over the last 30 years, it has 
become clear that PMBL differs in pathogenesis, clinical 
presentation and clinical course. PMBL is thought to 
arise from thymic medullary B cells, has a high incidence 
among young women, and is characterized by aggressive 
local invasion. With chemoimmunotherapy (e.g. R-CHOP 
scheme), PMBL now carries a relatively good prognosis 
and  novel  strikingly  efficient  treatment  options  have 
been reported [3]. Thus, PMBL has come full circle from 
recognition to effective oncologic management. While 
primary treatment failure is uncommon, when it occurs, 
it  is  often  rapid  and  difficult  to  treat. Thus,  evolving 
treatment paradigms now aim to incorporate an expanded 
understanding of the underlying molecular-genetic 
aberrations of this particular lymphoma [2].
PMBL is also genetically distinct and the presence 
of the anti-apoptotic and pro-proliferative factors BCL6 
and pSTAT6 are two key molecular features of PMBL. 
Recently, combined targeting of BCL6 and activated 
STAT6 via specific chemical inhibitors resulted in additive 
efficacy regarding the negative effects on cell viability in 
PMBL [4]. Notably, the distribution of these factors in 
clonal cell lines was heterogenous with a distribution of 
BCL6 and STAT6 to mutually exclusive subsets of cells 
[4]. Given the partial dependence from each of these 
co-existent oncogenic factors, Häberle et al. in a recent 
issue of oncoscience [5], evaluated whether molecular 
targeting of each factor in combination with components 
of the current chemoimmunotherapy (R-CHOP) holds 
therapeutic potential.
Specifically,  the  authors  combined  si-RNA 
mediated knock-down of either BCL6 or STAT6 in all 
three currently available PMBL cell lines with subsequent 
treatment with doxorubicin, rituximab, or vincristine. 
Notably, the authors applied doses that had little to no 
effect by themselves; doxorubicin 0.1nM (IC50:100nm), 
vincristine 0.1nM (IC50:2.7nM), and rituxamib 1µg/ml 
(vs. typically applied at 10µg/ml). With some variability, 
the authors’ report that in two of the three cells lines 
(K1106 and U2940), initial depletion of one subset 
of cells (i.e., BCL6 or STAT6), renders the remaining 
cells hypersensitive to the low-dose components of the 
chemoimmunotherapy (Figure 1). While the authors did 
not report whether dual knock-down of BCL6 and STAT6 
had a similar (over even more pronounced) sensitizing 
effect and it remains to be determined whether the same 
sensitization occurs with the previously reported chemical 
inhibitors, the data by Häberle et al. [5] are important for 
several reasons: 
First, in the current study the authors report a 
lack of sensitization in one of the PMBL cell lines that 
harbors STAT6 mutations (MedB-1). These ‘negative’ 
data underscore the importance of delineating the specific 
role of STAT6 mutations in PMBL. Actually, the same 
group described mutations in the DNA-binding domain 
of STAT6 in ~36% of PMBL cases [6]. Collectively these 
data suggest that STAT6 mutant cases may represent 
a distinct subset of PMBL cases – at least with respect 
to sensitization to chemotherapy using prior BCL6 and/
or STAT6 depletion. However, these notions remain 
speculative until the functional, clinicopathological or 
prognostic implications of STAT6 mutations in PMBL 
have been delineated. 
Second, in combination with the prior report on 
intratumoral heterogeneity in PMBL, the current data 
underscore that targeting specific molecular aberrations 
deteriorates an apparent micro-organization between 
PMBL cells. Specifically, each cell line is composed of 
for example BCL6-positive and BCL6-negative subsets 
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Figure 1: BCL6 knock-down induced 
chemosensitization in PMBL (data from [5]).Oncotarget 10966 www.impactjournals.com/oncotarget
of cells. Now the group reports that si-RNA mediated 
elimination of part of the cellular population (e.g., 
BCL6) renders the remaining cells highly sensitive to 
components the R-CHOP regimen. This demonstration of 
an apparent intricate interplay between cells in a clonal 
population falls at first glance in line with several studies 
on intratumoral heterogeneity. However, demonstrating 
chemosensitization in a lymphoma provides an elegant 
and therapeutically relevant rational for a more in-
depth understanding of the intratumoral architecture of 
PMBL. In fact, the demonstrated molecularly-targeted 
reprogramming –via elimination of one subset of cells– 
emphasizes that the cellular composition of a lymphoma 
may not be as monomorphous as previously assumed. 
While the precise mechanism underlying the 
described sensitization remains to be determined, clinical 
trials employing JAK/STAT inhibitors are ongoing 
and solid preclinical data on novel BCL6 inhibitors are 
available [7]. Thus the study by Häberle et al. [5] is 
noteworthy because it delivers proof of principle that the 
combination of novel molecular strategies with established 
therapies may hold potential clinical value in PMBL.
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